DSHEA not intended to "undermine" drug regulatory regime, Merck tells FDA.
This article was originally published in The Tan Sheet
Executive Summary
DSHEA NOT INTENDED TO "UNDERMINE" DRUG REGULATORY REGIME, Merck asserts in comments to FDA on the regulatory status of Cholestin. In opposition to claims by Pharmanex that Cholestin is marketed squarely within the Dietary Supplement Health & Education Act as a dietary supplement, Merck declares the law "was not designed to undermine the drug regulatory regime (with its incentives and protections to develop new drugs, including orphan drugs), by giving rise to an unregulated generic drug market for `dietary ingredients.'"
You may also be interested in...
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands
People In Brief
Perrigo promotes in pricing, planning